Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.
Company Growth (employees)
New York, US
Size (employees)
116 (est)
Synergy Pharmaceuticals is headquartered in New York, US

Synergy Pharmaceuticals Office Locations

Synergy Pharmaceuticals has an office in New York
New York, US (HQ)
420 Lexington Ave

Synergy Pharmaceuticals Financials and Metrics

Synergy Pharmaceuticals Financials


Revenue (Q2, 2017)

2.3 m

Gross profit (Q2, 2017)

(576 k)

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(73.9 m)

EBIT (Q2, 2017)

(73.6 m)

Market capitalization (13-Dec-2017)

452.2 m

Cash (30-Jun-2017)

82 m
Synergy Pharmaceuticals's current market capitalization is $452.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


(176.8 m)(94.3 m)(99.8 m)(42.4 m)

Net Income

(171.2 m)(95.7 m)(117.5 m)(198.6 m)
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


98 k2.3 m

Cost of goods sold

1.8 m2.9 m

Gross profit

(1.7 m)(576 k)

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


18.1 m146.5 m61.7 m82.4 m

Accounts Receivable

554 k


3.7 m3.8 m3.3 m5.6 m

Current Assets

71.9 m200.2 m115.1 m88.9 m
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


12.1 m20.6 m12.8 m78.7 m61.7 m41.9 m84.2 m141.2 m109.1 m139.3 m82 m

Accounts Receivable

6.3 m1.8 m


9.6 m11.9 m

Current Assets

87.3 m76.2 m36.9 m182.3 m164 m143.1 m87.5 m145.5 m110.8 m163.3 m104 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(62.1 m)(95.7 m)(117.5 m)(198.6 m)

Depreciation and Amortization

56 k120 k163 k233 k


(2.2 m)(124 k)531 k(5.6 m)

Accounts Payable

7.1 m316 k1.9 m11.5 m
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.5 m)(16.2 m)(23 m)(27.4 m)(61.1 m)(87.1 m)(59.9 m)(38.6 m)(40.2 m)(64.6 m)

Depreciation and Amortization

67 k103 k

Accounts Receivable

6.3 m


9.6 m
Y, 2017

Financial Leverage

2.4 x
Show all financial metrics

Synergy Pharmaceuticals Operating Metrics

Synergy Pharmaceuticals's Patent Applications was reported to be 3 in FY, 2016
FY, 2016

Patents (US)


Patent Applications


Patents (foreign)


Patents Pending

Show all operating metrics

Synergy Pharmaceuticals Market Value History

Synergy Pharmaceuticals's Web-traffic and Trends

Synergy Pharmaceuticals Online and Social Media Presence

Synergy Pharmaceuticals Company Life and Culture

You may also be interested in